Quick Answer
Sarepta Therapeutics, Inc. reported Total Revenue of $2.20 billion for fiscal year 2025.
Sarepta Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $2.20B +15.6% |
$1.90B +53.0% |
$1.24B +33.3% |
$933.01M +32.9% |
$701.89M +30.0% |
$540.10M +41.8% |
| Revenue (ASC 606) | $1.86B +4.3% |
$1.79B +56.2% |
$1.14B +35.7% |
$843.77M +37.8% |
$612.40M +34.3% |
$455.87M +19.7% |
| Net Income | -$713.41M -403.3% |
$235.24M +143.9% |
-$535.98M +23.8% |
-$703.49M -68.0% |
-$418.78M +24.4% |
-$554.13M +22.5% |
| Diluted EPS | -$7.13 -404.7% |
$2.34 +140.3% |
-$5.80 +27.8% |
-$8.03 -55.9% |
-$5.15 +27.6% |
-$7.11 |
| Total Assets | $3.35B -15.5% |
$3.96B +21.4% |
$3.26B +4.4% |
$3.13B -0.6% |
$3.15B +5.5% |
$2.98B +63.7% |
| Cash and Equivalents | $801.28M -27.4% |
$1.10B +157.5% |
$428.43M -55.7% |
$966.78M -54.3% |
$2.12B +40.8% |
$1.50B +79.9% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $1.14B -25.3% |
$1.53B +77.8% |
$859.34M +123.2% |
$384.95M -58.5% |
$928.01M +21.8% |
$761.76M -6.9% |
| R&D Expense | — | — | — | — | — | — |
| Operating Income | -$699.78M -420.9% |
$218.08M +181.4% |
-$267.82M +50.1% |
-$536.20M -16.6% |
-$459.71M +18.5% |
-$564.16M +20.0% |
| Shares Outstanding | 104.96M +8.3% |
96.90M +3.4% |
93.73M +6.6% |
87.95M +0.9% |
87.13M +9.8% |
79.37M +5.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $399.36M | -14.5% | -34.6% |
| Revenue (ASC 606) | September 30, 2025 | $370.04M | -13.9% | -27.9% |
| Net Income | September 30, 2025 | -$179.95M | -635.4% | -191.4% |
| Diluted EPS | September 30, 2025 | -$1.80 | -629.4% | -195.2% |
| Total Assets | September 30, 2025 | $3.49B | -3.0% | -5.1% |
| Cash and Equivalents | September 30, 2025 | $613.08M | +209.9% | +20.1% |
| Long-Term Debt | March 31, 2015 | $1.45M | -6.5% | -1.8% |
| Stockholders Equity | September 30, 2025 | $1.32B | +8.1% | -2.7% |
| R&D Expense | June 30, 2019 | $113.27M | -7.8% | +25.1% |
| Operating Income | September 30, 2025 | -$103.39M | -565.8% | -189.5% |
| Shares Outstanding | September 30, 2025 | 104.77M | +9.7% | +7.2% |
- Sarepta Therapeutics, Inc. reported Total Revenue of $2.20 billion for fiscal year 2025.
- Sarepta Therapeutics, Inc. showed an increase of +15.6% in Total Revenue compared to the prior fiscal year.
- Sarepta Therapeutics, Inc. reported Revenue (ASC 606) of $1.86 billion for fiscal year 2025.
- Sarepta Therapeutics, Inc. showed an increase of +4.3% in Revenue (ASC 606) compared to the prior fiscal year.
- Sarepta Therapeutics, Inc. reported Net Income of -$713.41 million for fiscal year 2025.
- Sarepta Therapeutics, Inc. showed a decrease of -403.3% in Net Income compared to the prior fiscal year.
- Sarepta Therapeutics, Inc. reported Diluted EPS of $7.13 per share (loss) for fiscal year 2025.
- Sarepta Therapeutics, Inc. showed a decrease of -404.7% in Diluted EPS compared to the prior fiscal year.
- Sarepta Therapeutics, Inc. reported Total Assets of $3.35 billion for fiscal year 2025.
- Sarepta Therapeutics, Inc. showed a decrease of -15.5% in Total Assets compared to the prior fiscal year.
- Sarepta Therapeutics, Inc. reported Cash and Equivalents of $801.28 million for fiscal year 2025.
- Sarepta Therapeutics, Inc. showed a decrease of -27.4% in Cash and Equivalents compared to the prior fiscal year.
- Sarepta Therapeutics, Inc. reported Long-Term Debt of $1.48 million for fiscal year 2014.
- Sarepta Therapeutics, Inc. showed a decrease of -6.3% in Long-Term Debt compared to the prior fiscal year.
- Sarepta Therapeutics, Inc. reported Stockholders Equity of $1.14 billion for fiscal year 2025.
- Sarepta Therapeutics, Inc. showed a decrease of -25.3% in Stockholders Equity compared to the prior fiscal year.
- Sarepta Therapeutics, Inc. reported R&D Expense of $401.84 million for fiscal year 2018.
- Sarepta Therapeutics, Inc. showed an increase of +141.0% in R&D Expense compared to the prior fiscal year.
- Sarepta Therapeutics, Inc. reported Operating Income of -$699.78 million for fiscal year 2025.
- Sarepta Therapeutics, Inc. showed a decrease of -420.9% in Operating Income compared to the prior fiscal year.
- Sarepta Therapeutics, Inc. reported Shares Outstanding of 104.96 million shares for fiscal year 2025.
- Sarepta Therapeutics, Inc. showed an increase of +8.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: